GalNAc-LNPs (Table S1) were formulated with an adenine base editor 8.8-m (ABE8.8) mRNA and a guide RNA (gRNA) targeting the mouse Angptl3 or Pcsk9 genes—well-validated therapeutic targets for the treatment of hypercholesterolemia. Here, ANGPTL3 is linked to familial hypercholesterolemia.